Maternal Serum Analyte Screening for Fetal Aneuploidy

被引：1

作者：

Chasen, Stephen T. ^{[1
,2
]}

机构：

[1] New York Presbyterian Hosp, New York, NY USA

[2] Weill Cornell Med Coll, New York, NY 10021 USA

来源：

CLINICAL OBSTETRICS AND GYNECOLOGY | 2014年 / 57卷 / 01期

关键词：

serum screening; fetal aneuploidy; Down syndrome; HUMAN CHORIONIC-GONADOTROPIN; FREE BETA-HCG; PLASMA PROTEIN-A; ALPHA-FETOPROTEIN; DOWN-SYNDROME; 1ST TRIMESTER; PAPP-A; NUCHAL TRANSLUCENCY; TWIN PREGNANCIES; 2ND-TRIMESTER;

D O I：

10.1097/GRF.0000000000000017

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In the first and second trimesters, chemicals produced by the fetoplacental unit are measured to assess risks of fetal abnormalities. Consistent associations between levels of these proteins in such pregnancies enable these biomarkers to be used to calculate risk for Down syndrome and other chromosomal abnormalities in individual pregnancies. Special consideration may be required when assessing risk in multiple pregnancies and pregnancies achieved with infertility therapy.

引用

页码：182 / 188

页数：7

共 50 条

[31] The impact of preimplantation genetic testing on first- and second-trimester maternal serum analyte levels
Gulersen, Moti
Krantz, David
Li, Xueying
Peyser, Alexandra
Goldman, Randi
Mullin, Christine
Bornstein, Eran
Rochelson, Burton
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2022, 35 (26) : 10435 - 10443
[32] The impact of fetal gender on first trimester nuchal translucency and maternal serum free β-hCG and PAPP-A MoM in normal and trisomy 21 pregnancies
Cowans, Nicholas J.
Stamatopoulou, Anastasia
Mainz, Nerea
Spencer, Kevin
Nicolaides, Kypros H.
PRENATAL DIAGNOSIS, 2009, 29 (06) : 578 - 581
[33] Second-trimester maternal serum analyte levels associated with fetal trisomy 13
Saller, DN
Canick, JA
Blitzer, MG
Palomaki, GE
Schwartz, S
Blakemore, KJ
Haddow, JE
PRENATAL DIAGNOSIS, 1999, 19 (09) : 813 - 816
[34] Stepwise sequential screening for fetal aneuploidy
Benn, Peter A.
Campbell, Winston A.
Zelop, Carolyn M.
Ingardia, Charles
Egan, James F. X.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (03) : 312.e1 - 312.e5
[35] Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers
Gaccioli, Francesca
Aye, Irving L. M. H.
Sovio, Ulla
Charnock-Jones, D. Stephen
Smith, Gordon C. S.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2018, 218 (02) : S725 - S737
[36] First-Trimester Serum-Based Screening for Aneuploidy in Pregnancy Achieved by Assisted Reproductive Technology
Wang, Ding
Chen, Rui
Wei, Guanhui
Xian, Yexing
Xie, Yingjun
Sun, Xiaofang
JOURNAL OF REPRODUCTIVE MEDICINE, 2020, 65 (7-8) : 240 - 248
[37] First and Second Trimester Markers of Fetal Aneuploidy in Pregnant Women with HIV Infection
Spencer, Kevin
FETAL DIAGNOSIS AND THERAPY, 2011, 29 (02) : 135 - 138
[38] Clinical Practice Guidelines for Prenatal Aneuploidy Screening and Diagnostic Testing from Korean Society of Maternal-Fetal Medicine: (1) Prenatal Aneuploidy Screening
Choe, Seung-Ah
Seol, Hyun-Joo
Kwon, Ji Young
Park, Chan-Wook
Kim, Minhyoung
Lee, Ji Yeon
Kim, Min-A
Hwang, Han-Sung
Na, Sunghun
Shim, Jae-Yoon
Kim, Kunwoo
Ryu, Hyun Mee
JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (04)
[39] The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy
Spencer, K
Bindra, R
Cacho, AM
Nicolaides, KH
PRENATAL DIAGNOSIS, 2004, 24 (03) : 169 - 173
[40] Relationship between maternal thyroid hormones and the biochemical markers of the first trimester aneuploidy screening
Aytan, Hakan
Caliskan, Ahmet C.
Demirturk, Fazli
Sahin, Semsettin
Erdogan, Filiz
Kuzu, Zehra
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 287 (06) : 1125 - 1129

← 1 2 3 4 5 →